318 related articles for article (PubMed ID: 23762225)
1. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
[TBL] [Abstract][Full Text] [Related]
2. Biomarker identification with ligand-targeted nucleoprotein assemblies.
Singer EM; Crocitto LE; Choi Y; Loera S; Weiss LM; Imam SA; Wilson TG; Smith SS
Nanomedicine (Lond); 2011 Jun; 6(4):659-68. PubMed ID: 21718176
[TBL] [Abstract][Full Text] [Related]
3. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
4. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
Jia X; Sun Y; Wang B
IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296
[TBL] [Abstract][Full Text] [Related]
5. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
6. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
Zenzmaier C; Sampson N; Plas E; Berger P
Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
9. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
Tanaka M; Suzuki Y; Takaoka K; Murakami S; Suzuki N; Shimazaki J
Int J Urol; 1999 Dec; 6(12):600-6. PubMed ID: 10609542
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy.
Coogan CL; Bostwick DG; Bloom KJ; Gould VE
Urology; 2003 Jan; 61(1):248-52. PubMed ID: 12559317
[TBL] [Abstract][Full Text] [Related]
12. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma.
Tomas D; Kruslin B
Prostate; 2004 Dec; 61(4):324-31. PubMed ID: 15389817
[TBL] [Abstract][Full Text] [Related]
13. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia.
Schauer IG; Ressler SJ; Tuxhorn JA; Dang TD; Rowley DR
Urology; 2008 Jul; 72(1):205-13. PubMed ID: 18314176
[TBL] [Abstract][Full Text] [Related]
14. Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases.
Gaudin PB; Rosai J; Epstein JI
Am J Surg Pathol; 1998 Feb; 22(2):148-62. PubMed ID: 9500215
[TBL] [Abstract][Full Text] [Related]
15. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
16. Expression of redox pathway enzymes in human prostatic tissue.
Valdman A; Häggarth L; Cheng L; Lopez-Beltran A; Montironi R; Ekman P; Egevad L
Anal Quant Cytol Histol; 2009 Dec; 31(6):367-74. PubMed ID: 20698352
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
Matsuda T; Fujime M; Suda K
Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
[TBL] [Abstract][Full Text] [Related]
18. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
19. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.
Popovics P; Awadallah WN; Kohrt SE; Case TC; Miller NL; Ricke EA; Huang W; Ramirez-Solano M; Liu Q; Vezina CM; Matusik RJ; Ricke WA; Grabowska MM
Prostate; 2020 Jul; 80(10):731-741. PubMed ID: 32356572
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
